On Nov. 3rd, Wall Street rendered a swift and brutal verdict on Kimberly-Clark's (NASDAQ: KMB) transformative acquisition of ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

In one of the most significant consumer-goods mergers of the year, Kimberly-Clark is buying Tylenol maker Kenvue in a ...

A £30 billion takeover shakes up the consumer health sector as Kimberly-Clark, the maker of Huggies nappies, prepares to ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

A price-sensitive, value-conscious consumer adds a degree of unevenness and uncertainty to a robust earnings season.

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

It pays a semiannual dividend and yields 4.4% based on the two most recent payments. Morningstar Equity analysts note that the firm pays out roughly 50% of its earnings as dividends, which is about ...

Kimberly-Clark, the maker of Huggies, said Monday it will acquire Kenvue, Tylenol’s parent, in a cash-and-stock transaction valued at nearly $50 billion. The companies said the combined portfolio will ...